City Therapeutics Overview
- Year Founded
-
2023
- Status
-
Public
- Employees
-
81
- Stock Symbol
-
CTY
- Share Price
-
$18.10
- (As of Friday Closing)
City Therapeutics General Information
Description
City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.
Contact Information
Website
www.citytx.comCorporate Office
- 399 Binney Street
- Cambridge, MA 02142
- United States
Corporate Office
- 399 Binney Street
- Cambridge, MA 02142
- United States
City Therapeutics Timeline
City Therapeutics Stock Performance
As of 13-Nov-2026, City Therapeutics’s stock price is $18.10. Its current market cap is $911M with 50.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $18.10 | $18.98 | $15.81 - $23.88 | $911M | 50.3M | 345K | -$2.53 |
City Therapeutics Financials Summary
As of 30-Jun-2026, City Therapeutics has a trailing 12-month revenue of $14.3M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 |
|---|---|---|---|
| Revenue | 14,342 | 13,562 | 2,778 |
| EBITDA | (86,835) | (59,284) | (29,361) |
| Net Income | (87,666) | (58,505) | (27,836) |
| Total Assets | 208,611 | 149,768 | 145,353 |
| Total Debt | 57,037 | 67,284 | 22,295 |
City Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
City Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
City Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
City Therapeutics Patents
City Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026226966-A1 | Peptide ligand-mediated delivery | Pending | 24-Apr-2025 | ||
| WO-2026198751-A1 | Rnai agents targeting transferrin receptor 2 (tfr2) | Pending | 19-Mar-2025 | ||
| WO-2026173945-A1 | Rnai agents targeting retinol binding protein 4 (rbp4) | Pending | 11-Feb-2025 | ||
| WO-2026117631-A2 | Factor xi rnai agent compositions and methods of use thereof | Pending | 26-Nov-2024 | ||
| WO-2026117631-A3 | Factor xi rnai agent compositions and methods of use thereof | Pending | 26-Nov-2024 | C12N15/113 |
City Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
City Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
City Therapeutics FAQs
-
When was City Therapeutics founded?
City Therapeutics was founded in 2023.
-
Where is City Therapeutics headquartered?
City Therapeutics is headquartered in Cambridge, MA.
-
What is the size of City Therapeutics?
City Therapeutics has 81 total employees.
-
What industry is City Therapeutics in?
City Therapeutics’s primary industry is Drug Discovery.
-
Is City Therapeutics a private or public company?
City Therapeutics is a Public company.
-
What is City Therapeutics’s stock symbol?
The ticker symbol for City Therapeutics is CTY.
-
What is the current stock price of City Therapeutics?
As of 13-Nov-2026 the stock price of City Therapeutics is $18.10.
-
What is the current market cap of City Therapeutics?
The current market capitalization of City Therapeutics is $911M.
-
What is City Therapeutics’s current revenue?
The trailing twelve month revenue for City Therapeutics is $14.3M.
-
What is City Therapeutics’s annual earnings per share (EPS)?
City Therapeutics’s EPS for 12 months was -$2.53.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
